Treatments for AF are getting a huge boost by Sentara Heart Hospital through an innovative AF treatment procedure was recently successfully performed there.

Surgeons and cardiologists at the hospital are now the first in the world to perform the Dual Epicardial Endocardial Persistent AF Study (Staged DEEP) surgical feasibility trial. This new procedure was performed by Jonathan Philpott, M.D., director of the Sentara AF Surgery Program, along with cardiac electrophysiologist collaborator Ian Woollett, M.D., of Cardiovascular Associates. The Staged DEEP trial was created as way of finding out how safe and effective the procedure was.

According to an article published online at, the study is conducted when doctors “create lines of block on the outside of the heart working through tiny chest incisions. During the same hospital stay, an electrophysiologist tests the surgical lines and then completes additional ablation lines using tiny catheters within the heart.”

“We believe that this staged hybrid procedure has the potential to represent an important advancement in the treatment of persistent forms of AF,” commented Robert Bernstein, M.D., a leading electrophysiologist in Norfolk, Va., and one of four electrophysiologists at Sentara collaborating in the trial. “Our initial experience with this hybrid procedure suggests that it represents a highly promising AF treatment.”

Atrial fibrillation is a serious condition that causes the heart to beat irregularly. The condition is treated with numerous medications, including the anticoagulant Multaq. Research has shown that Multaq causes liver failure and a worsening of the heart condition for some patients.

If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.